AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Sym... ( CASTLE ROCK Colo. Aug. 23 /- Aspe...)

AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol 'APPY'

Date:8/23/2007

CASTLE ROCK, Colo., Aug. 23 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (OTC Bulletin Board: APNB) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, today announced its application to list its common stock on the NASDAQ Capital Markets Stock Exchange has been approved.

The company anticipates its shares of common stock will begin trading on the NASDAQ CM commencing with the open of trading on Tuesday, August 28, 2007, under the symbol "APPY". Until then, AspenBio Pharma's common stock will continue to trade on the OTC Bulletin Board ("OTC BB") under the symbol "APNB."

Richard Donnelly, CEO of AspenBio Pharma, said, "Our listing on the NASDAQ Capital Markets represents yet another important milestone for our company, especially as our high-value products advance to the final stages of their development and we take additional steps toward FDA approval and commercialization. This will certainly help to raise the company's visibility in the financial markets and substantially enhance shareholder value."

AspenBio Pharma's chairman, Greg Pusey, added, "Increasing shareholder value has always been our top priority. Our share value has increased more than 650% during the last twenty-four months as our stock traded on the OTC BB. Now our loyal investors will continue to be rewarded with the many benefits provided by a NASDAQ listing."

One of AspenBio's key products is a specialized assay that detects a marker in the blood associated with appendicitis. According to three pre- United States Food and Drug Administration ("FDA") studies conducted during the past 33 months, including an ongoing 400 patient study, the company's AppyScore(TM) blood test has been able to identify patients with appendicitis at a very high sensitivity level of 94% to 97%. This compares to significantly lower diagnostic success rates for expensive CT scans, which are generally considered the best
'/>"/>

2

GOOD

Page: 1 2 3 4
Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango

Post Your Comments:

AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Sym...( CASTLE ROCK Colo. Aug. 23 /- Aspe...)